Imagine a future where a single therapy could revolutionize the treatment of cancer and Alzheimer's disease. This bold vision is what drives Samir Ounzain, CEO of HAYA Therapeutics, a science startup with a mission to transform medicine.
In a recent interview, Ounzain shared his insights on entrepreneurship, the challenges of bringing innovative therapies to market, and why he chose Switzerland as his startup's base.
The Swiss Advantage
Ounzain, a British national, chose Switzerland for its excellent support for startups and its rich legacy in the pharmaceutical industry. He highlights the access to talent, both locally trained and European professionals drawn by the country's high quality of life and professional opportunities.
"Switzerland is an ideal hub for translating academic ideas into commercial products," he says.
HAYA Therapeutics, founded in 2019, is currently developing a therapy for heart failure, but their ambition extends far beyond. They aim to pioneer an approach that turns sick cells back into healthy ones, a methodology that could be applied to a wide range of diseases.
Global Perspective, Local Challenges
While Switzerland offers many advantages, Ounzain acknowledges the country's limitations when it comes to scaling up startups. He notes that it is rare for Swiss startups, especially in the life sciences sector, to reach 'unicorn' status (valued at over $1 billion) within their first decade.
This challenge is further exacerbated by Swiss tax laws, which require company founders to pay heavy taxes based on the virtual valuation of their startups. Ounzain explains that this tax can amount to around 1% of the valuation set by external investors, a significant burden for founders.
"Finding a solution to this challenge would greatly benefit the Swiss startup ecosystem," he adds.
Funding and Market Access
HAYA Therapeutics has raised an impressive $90 million, largely from foreign investors based in the US and EU. This funding has enabled them to establish an affiliate in San Diego, bringing them closer to the US market, experienced biotech operators, and US investors.
"American investors typically have a significant appetite for risk and bold ideas," Ounzain notes.
The startup's next steps include navigating the costly and extensive phase 3 clinical trials, which typically cost around $1 billion. Ounzain believes that their strong track record and recognition as a Technology Pioneer by the World Economic Forum will help them secure the necessary funding, whether through growth funds, partnerships, or an IPO on Nasdaq.
A Targeted Approach, Global Impact
HAYA Therapeutics' lead product, HTX-001, is a targeted therapy for heart failure, focused on non-obstructive hypertrophic cardiomyopathy. If successful, this therapy could pave the way for treating a wide range of common, chronic, and age-related diseases.
"Our methodology is naturally programmable and relatively easy to scale up, keeping manufacturing and overall costs low," Ounzain explains.
As the startup navigates the complex landscape of drug development and regulatory approval, they remain committed to their mission: bringing safe, effective, and accessible medicines to up to ten million patients in need.
And this is where your thoughts come in...
What are your thoughts on the future of healthcare innovation? Do you think startups like HAYA Therapeutics can revolutionize the industry? Share your insights and let's spark a discussion!
